Simplify Propel Opportunities ETF SURI
Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed
- Net expense ratio
- 2.56%
- Net assets
- $77.3M
- Holdings
- 39
- 12-month distribution yield
- 16.14%
- Asset class
- Multi-asset
Simplify Propel Opportunities ETF (SURI) is an exchange-traded fund listed on NYSE Arca in the United States, issued by Simplify. Its category is Multi-asset · US (multi-asset). Its last price was US$16.85 on 20 Oct 2026. Its net expense ratio is 2.56% a year, from its prospectus dated 19 May 2026. It reported net assets of US$77.25 million as of 30 Jun 2026. Its latest holdings report lists 39 holdings as of 30 Jun 2026. Over the last 12 months it paid distributions of US$2.72 a unit, a 12-month distribution yield of 16.14%, paid quarterly.
Fees
- Total annual operating expenses (gross)
- 2.81%
- Net, after fee waivers or reimbursements
- 2.56%
- Management fee
- 2.75%
- Prospectus date
- 19 May 2026
- Filed with the SEC
- 18 May 2026
Size and reporting
- Net assets
- $77,252,814
- Total assets
- $135,734,764
- Holdings as of
- 30 Jun 2026
- Report made public
- 24 Aug 2026 (55 days after the month end)
Top holdings
Largest 25 of 39 positions, as of 30 Jun 2026. Weight is the percent of net assets the fund reported.
| # | Holding | Identifier | Weight | Value (USD) | Type | Country | Currency |
|---|---|---|---|---|---|---|---|
| 1 | UNITED STATES OF AMERICA - BUREAU OF THE PUBLIC DEBT B 0 10/20/26 | US912797VM69 | 76.77% | $59.3M | Debt | United States | USD |
| 2 | MORGAN STANLEY & CO. LLC | No identifier reported | -75.22% | -$58.1M | Repurchase agreements | United States | USD |
| 3 | PLAINS GP HOLDINGS LP PLAINS GP HOLDINGS LP LTD PARTNR INT A | US72651A2078 | 39.97% | $30.9M | Equity (common) | United States | USD |
| 4 | ACHIEVE LIFE SCIENCES INC ACHIEVE LIFE SCIENCES INC COM | US0044685008 | 12.11% | $9.4M | Equity (common) | United States | USD |
| 5 | MILESTONE PHARMACEUTICALS INC MILESTONE PHARMACEUTICALS INC COM | CA59935V1076 | 5.81% | $4.5M | Equity (common) | Canada | USD |
| 6 | ACHIEVE LIFE SCIENCES INC ACHIEVE LIFE SCIENCES INC WT EXP 063030 | US0044681874 | 4.42% | $3.4M | Equity (common) | United States | USD |
| 7 | DELCATH SYSTEMS INC DELCATH SYSTEMS INC COM NEW | US24661P8077 | 4.26% | $3.3M | Equity (common) | United States | USD |
| 8 | PHATHOM PHARMACEUTICALS INC PHATHOM PHARMACEUTICALS INC COM | US71722W1071 | 3.50% | $2.7M | Equity (common) | United States | USD |
| 9 | CORCEPT THERAPEUTICS INC CORCEPT THERAPEUTICS INC COM | US2183521028 | 2.98% | $2.3M | Equity (common) | United States | USD |
| 10 | ABEONA THERAPEUTICS INC ABEONA THERAPEUTICS INC COM NEW | US00289Y2063 | 2.76% | $2.1M | Equity (common) | United States | USD |
| 11 | CELLDEX THERAPEUTICS INC CELLDEX THERAPEUTICS INC COM NEW | US15117B2025 | 2.56% | $2.0M | Equity (common) | United States | USD |
| 12 | KYVERNA THERAPEUTICS INC KYVERNA THERAPEUTICS INC COM | US5019761049 | 2.11% | $1.6M | Equity (common) | United States | USD |
| 13 | COMPASS PATHWAYS PLC COMPASS PATHWAYS PLC SPONSORED ADS | US20451W1018 | 2.09% | $1.6M | Equity (common) | United Kingdom | USD |
| 14 | LEONABIO INC LEONABIO INC COM | US04746L2034 | 1.78% | $1.4M | Equity (common) | United States | USD |
| 15 | INVENTIVA SA INVENTIVA SA ADS | US46124U1079 | 1.53% | $1.2M | Equity (common) | France | USD |
| 16 | AQUESTIVE THERAPEUTICS INC AQUESTIVE THERAPEUTICS INC COM | US03843E1047 | 1.50% | $1.2M | Equity (common) | United States | USD |
| 17 | ARTIVA BIOTHERAPEUTICS INC ARTIVA BIOTHERAPEUTICS INC COM | US04317A1079 | 1.27% | $983K | Equity (common) | United States | USD |
| 18 | ZEVRA THERAPEUTICS INC ZEVRA THERAPEUTICS INC COM NEW | US4884452065 | 1.25% | $966K | Equity (common) | United States | USD |
| 19 | ORCHESTRA BIOMED HOLDINGS INC ORCHESTRA BIOMED HOLDINGS INC COM | US68572M1062 | 1.23% | $947K | Equity (common) | United States | USD |
| 20 | PALISADE BIO INC PALISADE BIO INC COM | US6963894026 | 1.22% | $942K | Equity (common) | United States | USD |
| 21 | TELESAT CANADA / TELESAT LLC TELSAT 5.625 12/06/26 144A | US87952VAR78 | 1.16% | $895K | Debt | Canada | USD |
| 22 | OCULAR THERAPEUTIX INC OCULAR THERAPEUTIX INC COM | US67576A1007 | 1.03% | $796K | Equity (common) | United States | USD |
| 23 | ACHIEVE LIFE SCIEN RTS | No identifier reported | 0.97% | $748K | Equity (common) | United States | USD |
| 24 | EYEPOINT INC EYEPOINT INC COM NEW | US30233G2093 | 0.84% | $649K | Equity (common) | United States | USD |
| 25 | IMMUNIC INC IMMUNIC INC COM NEW | US4525EP2001 | 0.61% | $472K | Equity (common) | United States | USD |
Breakdowns
Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.
Asset type
| Type | Weight | Bar |
|---|---|---|
| Equity (common) | 97.77% | |
| Debt | 77.92% | |
| Repurchase agreements | -75.22% |
Country
| Country | Weight | Bar |
|---|---|---|
| United States | 89.87% | |
| Canada | 6.97% | |
| United Kingdom | 2.09% | |
| France | 1.53% |
Currency exposure
| Currency | Weight | Bar |
|---|---|---|
| US dollar (USD) | 100.47% |
Sector
| Sector | Weight | Bar |
|---|---|---|
| Energy | 39.97% | |
| Health Care | 4.01% | |
| Health Technology | 0.55% |
Source: SEC Form N-PORT (opens in a new tab) Holdings as of
Distributions
- Paid in the last 12 months
- $2.7200
- 12-month yield
- 16.14%
- Frequency
- Quarterly
- Latest ex-date
- 25 Sep 2026
12-month yield = distributions per unit with an ex-date in the last 12 months ($2.7200) ÷ latest price ($16.85) × 100 = 16.14%. It looks back, so it is not a forecast; special distributions in the window are included.
Why a distribution yield is not the fund's return: yield vs total return
Distribution history table (15 payments)
| Ex-date | Amount per unit |
|---|---|
| 25 Sep 2026 | $0.6800 |
| 25 Jun 2026 | $0.6800 |
| 26 Mar 2026 | $0.6800 |
| 23 Dec 2025 | $0.6800 |
| 25 Sep 2025 | $0.6800 |
| 25 Jun 2025 | $0.6800 |
| 26 Mar 2025 | $0.6800 |
| 23 Dec 2024 | $0.6800 |
| 25 Sep 2024 | $0.6800 |
| 25 Jun 2024 | $1.2500 |
| 25 Mar 2024 | $0.6800 |
| 26 Dec 2023 | $0.6800 |
| 27 Sep 2023 | $0.6800 |
| 27 Jun 2023 | $0.6800 |
| 27 Mar 2023 | $1.0000 |
Filings and sources
- Form N-PORT report for June 2026 (opens in a new tab)
- Prospectus filing with the fee table (opens in a new tab)
- All SEC filings for this fund series (S000078061) (opens in a new tab)
- Nasdaq Trader symbol directory (opens in a new tab)
- Yahoo Finance quote and distributions (opens in a new tab)
- How the ETF figures are collected
Compare with
Largest funds in the same category:
- SURI and FREI Fidelity Real Estate Income ETF
- SURI and AOR iShares Core 60/40 Balanced Allocation ETF
- SURI and AOA iShares Core 80/20 Aggressive Allocation ETF
- SURI and AOM iShares Core 40/60 Moderate Allocation ETF